J&J says Darza­lex, Carvyk­ti dri­ve Q1 phar­ma sales growth while medtech looms large

Last year
Pharma

No­var­tis show­cas­es Ph3 da­ta for Fab­hal­ta in IgAN as FDA grants pri­or­i­ty re­view

Last year
R&D
Pharma

GAO ex­am­ines state PBM reg­u­la­tion as Con­gress weighs wider re­forms

Last year
Pharma
FDA+

Gabrielle Union-Wade pro­motes self-ad­vo­ca­cy at me­dia agency health event

Last year
Pharma
Marketing

Fed­er­al judge grants pause to Pfiz­er, BioN­Tech in Covid-19 patent law­suit tri­al brought by Mod­er­na

Last year
Pharma
Law

New FDA tri­al in­no­va­tion cen­ter launch­es with demon­stra­tion to in­crease in­dus­try in­ter­ac­tions

Last year
Pharma
FDA+

FDA is ready to elim­i­nate the in­ter­change­abil­i­ty des­ig­na­tion for biosim­i­lars

Last year
FDA+

Ul­tragenyx preps for piv­otal tri­al in An­gel­man syn­drome, an area where oth­ers fell short: #AAN24

Last year
R&D

Mus­tang Bio to lay off work­ers; MaaT's new da­ta for mi­cro­bio­me ther­a­py

Last year
News Briefing

Mar­i­nus’ IV seizure drug faces ef­fi­ca­cy ques­tions as Ph3 con­tin­ues past in­ter­im analy­sis

Last year
R&D

Cash, chips and tal­ent: In­side Nvidi­a's plan to dom­i­nate biotech's AI rev­o­lu­tion

Last year
R&D
AI

Ex­clu­sive: Eat­ing dis­or­der tele­health start­up Equip rais­es $35M, ac­cord­ing to fil­ing

Last year
Financing
Health Tech

FDA hits Neumo­ra with clin­i­cal hold for schiz­o­phre­nia drug af­ter pre­clin­i­cal da­ta showed con­vul­sions in rab­bits

Last year
R&D

Re­gen­eron en­ters ven­ture in­vest­ing with $500M, poach­es se­nior part­ner from ARCH

Last year
People
Financing

Roche’s Columvi pass­es Phase 3 lym­phoma test as com­pe­ti­tion with Ab­b­Vie, Gen­mab con­tin­ues

Last year
R&D

Astel­las writes down an­oth­er piece of its Au­dentes gene ther­a­py ac­qui­si­tion

Last year
Pharma
Cell/Gene Tx

Ver­tex's $4.9B bet; Lay­offs at No­var­tis, Genen­tech, Sanofi; Star founders un­veil new star­tups; and more

Last year
Weekly

Ad­comm backs use of min­i­mal resid­ual dis­ease in mul­ti­ple myelo­ma ac­cel­er­at­ed ap­provals

Last year
Pharma
FDA+

Japan­ese phar­ma­ceu­ti­cal reg­u­la­tions un­der re­view to re­solve drug short­ages and en­sure sta­ble sup­ply

Last year
Nikkei Biotechnology

Ex­clu­sive: Health in­sur­ance bro­ker Go­Health trims jobs across de­part­ments

Last year
People
Health Tech

EMA probe finds no causal link be­tween semaglu­tide and sui­ci­dal thoughts, self-harm

Last year
Pharma
FDA+

Re­ci­pharm’s new CEO on ‘fast and fu­ri­ous’ changes, with eyes on GLP-1, bi­o­log­ics man­u­fac­tur­ing

Last year
Manufacturing

ADC deal­mak­ing is red hot. Is it sus­tain­able?

Last year
Deals
Pharma

Nurix's $175M of­fer­ing; In­vivyd CEO is out

Last year
News Briefing
First page Previous page 171172173174175176177 Next page Last page
A service from the Financial Times